News headlines about Vital Therapies (NASDAQ:VTL) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vital Therapies earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.5711038892123 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Vital Therapies (NASDAQ:VTL) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.01. During the same period in the prior year, the firm earned ($0.30) earnings per share.

Separately, ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Vital Therapies presently has an average rating of “Hold” and an average target price of $8.00.

COPYRIGHT VIOLATION WARNING: “Vital Therapies (VTL) Earning Somewhat Favorable News Coverage, Study Shows” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/25/vital-therapies-vtl-earning-somewhat-favorable-news-coverage-study-shows.html.

In other news, Director Muneer A. Satter acquired 130,000 shares of the stock in a transaction that occurred on Thursday, September 14th. The stock was purchased at an average cost of $4.01 per share, for a total transaction of $521,300.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jean Jacques Bienaime acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, September 13th. The stock was purchased at an average price of $4.00 per share, with a total value of $40,000.00. Following the completion of the transaction, the director now owns 65,119 shares of the company’s stock, valued at $260,476. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 190,000 shares of company stock valued at $737,800. Corporate insiders own 32.60% of the company’s stock.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.